An open-label, multi-center Phase I/II trial evaluating the safety and efficacy of azacitidine (Vidaza) in patients with acute myeloid leukaemia not eligible for or resistant to chemotherapy.
Phase of Trial: Phase I/II
Latest Information Update: 31 Oct 2011
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 25 Jul 2011 New trial record